Catalog No.
Product Name
Application
Product Information
Citations
-
AChE/BuChE Inhibitor
Feralolide is a dihydroisocoumarin that functions as a dual inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), exhibiting IC50 values of 55 μg/mL and 52 μg/mL, respectively. This compound also demonstrates antioxidant properties, effectively inhibiting 2,2-diphenyl-1-picrylhydrazyl (DPPH) and 2,2′-azinobis-3-ethylbenzothiazoline-6-sulfonic acid (ABTS). Feralolide may serve as a valuable tool in research focused on cognitive disorders, such as Alzheimer's disease, aiming to restore and enhance memory functions. -
Cholinesterase (ChE) Inhibitor
Echothiopate chloride is a potent, irreversible inhibitor of cholinesterase (ChE). By forming a covalent bond with the serine residue at the active site of ChE, it permanently inactivates the enzyme, necessitating de novo enzyme synthesis for restoration of activity. This long-lasting inhibition makes echothiopate chloride effective in ocular applications, particularly as a miotic agent in the management of chronic glaucoma and accommodative esotropia, with effects that can persist for over a week. -
AChE Inhibitor
Lycoramine is a dihydro-derivative of galanthamine that functions as a potent acetylcholinesterase (AChE) inhibitor. Isolated from the plant Lycoris radiata, it demonstrates significant potential in enhancing cholinergic signaling, making it a valuable reagent for research related to neurodegenerative diseases and cognitive disorders. Its inhibitory action on AChE may offer insights into therapeutic strategies for conditions such as Alzheimer's disease. -
Cholinesterase Inhibitor
AChE/BChE-IN-31 is a cholinesterase inhibitor targeting human acetylcholinesterase (hAChE) and equine butyrylcholinesterase (eqBChE). It demonstrates significant inhibitory activity against these enzymes, making it relevant for research on neurodegenerative diseases such as Alzheimer’s disease. Additionally, AChE/BChE-IN-31 exhibits antioxidant properties, with an IC50 value of 105.04 μM against DPPH, indicating its potential utility in studies related to oxidative stress. -
Cholinesterase Inhibitors; Lupane Derivative; Molecular Modeling; Triterpenoid
3β-Hydroxy-lup-20(29)-en-16-one is a potent dual inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), exhibiting a notable selectivity for BChE with an IC50 value of 28.9 μM. This lupane derivative serves as a valuable tool in the study of cholinergic signaling pathways and triterpenoid research. Its inhibitory properties position it as a potential candidate for neurodegenerative disease research applications, particularly in disorders characterized by cholinergic dysregulation. -
AChE/BChE Inhibitor
AChE/BChE-IN-24 is a potent inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), exhibiting IC50 values of 16.38 μM and 10.44 μM, respectively. This compound functions as a neuroprotective agent by preventing the breakdown of acetylcholine, thereby enhancing cholinergic neurotransmission. Its applications are particularly relevant in research related to neurodegenerative diseases and cognitive function disorders. -
AChE/BChE Inhibitor
Lakoochin C is a potent inhibitor of acetylcholinesterase (AChE) with an IC50 of 61.86 μM and butyrylcholinesterase (BChE) with an IC50 of 47.21 μM. This compound demonstrates significant biological activity in modulating cholinergic signaling, making it a valuable tool for research focused on neurodegenerative diseases such as Alzheimer's disease. Its application in studies of cholinergic dysfunction may provide insights into therapeutic strategies for memory-related disorders. -
AChE Inhibitor
AChE-IN-64 is a selective inhibitor of acetylcholinesterase (AChE) with an IC50 value of 36.9 µM. This compound is primarily utilized in research related to cognitive disorders, offering a valuable tool for the investigation of cholinergic dysfunction and its implications in conditions such as Alzheimer's disease and other neurodegenerative disorders. -
AChE Inhibitor
Quinolactacin A1 is a potent acetylcholinesterase (AChE) inhibitor derived from the solid-state fermentation of Penicillium citrinum 90648. It exhibits significant biological activity in inhibiting AChE, making it a valuable compound for studying neurodegenerative disorders, particularly Alzheimer's disease. Research applications include exploring therapeutic strategies and understanding the biochemical pathways associated with cholinergic dysfunction. -
AChE Inhibitor
Cyanofenphos is an orally active organophosphate compound that acts as an acetylcholinesterase (AChE) inhibitor, exhibiting neurotoxic properties. This reagent is associated with delayed neurotoxic effects, including ataxia and paralysis, and may present additional symptoms such as somnolence, decreased feed intake, and weight loss in avian models. Cyanofenphos demonstrates a self-antagonistic effect, whereby repeated low-dose pre-treatment can mitigate acute toxicity but exacerbate long-term neurotoxicity and decrease enzyme inhibition, with protective effects peaking 24 hours post-treatment. This compound is widely utilized in research focused on neurotoxicity and AChE inhibition pathways. -
Radioligand for Brain Imaging
TRV-7019 is a brain-penetrating radioligand that targets butyrylcholinesterase, facilitating advanced imaging techniques. This compound is instrumental for diagnostic applications related to amyloid diseases, multiple sclerosis, brain tumors, and the assessment of butyrylcholinesterase activity. Its specificity and ability to cross the blood-brain barrier make it a valuable tool for neurological research and clinical diagnostics. -
Caffeic Acid Ester Compound
2-Methyl-2-butenyl (E)-Caffeate is a caffeic acid ester compound that exhibits inhibitory activity against both acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). It also demonstrates significant antioxidant properties, making it a valuable reagent for studying oxidative stress. This compound is particularly relevant for research related to neurodegenerative diseases such as Alzheimer's disease. -
BChE Inhibitor
BChE-IN-9 (Azepano-11-deoxo-glycyrrhetol) is a mixed type inhibitor of butyrylcholinesterase (BChE) with a Ki value of 0.21 µM. This compound exhibits significant inhibitory activity, making it a valuable tool for studying cholinergic signaling pathways and neurodegenerative diseases where BChE is implicated. Its use in research can provide insights into therapeutic strategies for conditions such as Alzheimer's disease and other neurocognitive disorders. -
AChE Inhibitor
AChE-IN-21 is a potent and selective inhibitor of acetylcholinesterase (AChE), exhibiting an IC50 value of 2.66 nM. This compound demonstrates significant blood-brain barrier permeability in vitro, making it suitable for central nervous system research applications. AChE-IN-21 may be utilized in studies related to neurodegenerative diseases, such as Alzheimer's disease, by modulating cholinergic signaling pathways. -
Acetylcholinesterase Inhibitor
Quilostigmine is a potent acetylcholinesterase inhibitor with an IC50 of 148 nM in rat brain acetylcholinesterase. This orally active analogue of Physostigmine demonstrates prolonged efficacy in reducing tremors. Its mechanism of action makes it a valuable tool for research related to Alzheimer's disease and other cognitive disorders. -
BChE Inhibitor
BChE-IN-4 is a potent butyrylcholinesterase (BChE) inhibitor that effectively crosses the blood-brain barrier. This compound has demonstrated the ability to attenuate learning and memory deficits associated with cholinergic deficits in mouse models. BChE-IN-4 shows promise for research applications related to Alzheimer's disease, making it a valuable tool for investigations into cognitive dysfunction and neurotransmitter modulation. -
BChE Inhibitor
Bleformin A is a potent butyrylcholinesterase (BChE) inhibitor with an IC50 value of 5.2 μM. Isolated from the natural source Bletilla striata, this compound demonstrates significant biological activity that is relevant to neurodegenerative disorders. Bleformin A is primarily utilized in research related to Alzheimer's disease, providing insights into cholinergic system modulation. -
Acetylcholinesterase Inhibitor, Butyrylcholinesterase Inhibitor
Melineurine is a reversible mixed-type inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), exhibiting IC50 values of 95.3 μM for AChE and 28.0 μM for BChE. This compound is instrumental in the study of neurodegenerative disorders, particularly Alzheimer's disease, due to its effects on cholinergic signaling. Melineurine serves as a valuable tool for investigating the role of cholinesterase inhibition in cognitive function and related therapeutic strategies. -
Copper Chelator
SON38 is a copper chelator that selectively binds divalent copper ions. This compound exhibits inhibitory effects on cholinesterase activity, making it a valuable tool for research into Alzheimer's disease and related neurodegenerative disorders. Its ability to modulate copper levels underscores its potential in studying copper's role in various biological processes. -
AChE Inhibitor
Fasciculin-II is a potent inhibitor of acetylcholinesterase (AChE), an enzyme critical for neurotransmitter regulation. By blocking AChE activity, Fasciculin-II enhances cholinergic transmission, making it a valuable tool for research in neurobiology and related fields. Its biological activity is particularly relevant in studies of synaptic function and neurodegenerative diseases. -
AChE/BChE/MAO-B Inhibitor
AChE/BChE/MAO-B-IN-1 is a reversible inhibitor targeting acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and monoamine oxidase B (MAO-B), exhibiting IC50 values of 7.31 μM, 0.56 μM, and 26.1 μM, respectively. This compound effectively crosses the blood-brain barrier and demonstrates neuroprotective properties while maintaining a lack of cytotoxicity. Its multifaceted inhibition profile makes it a valuable tool for research on neurodegenerative diseases and associated pathways. -
Dual MAO-AChE Inhibitor
MAO-A/B-IN-3 is a dual inhibitor targeting both monoamine oxidase A (MAO-A) and monoamine oxidase B (MAO-B), as well as acetylcholinesterase (AChE). With IC50 values of 67 nM for MAO-A, 29 nM for MAO-B, and 1370 nM for AChE, this compound demonstrates substantial multi-target efficacy. MAO-A/B-IN-3 modifies key binding sites to enhance its inhibitory activity against MAO enzymes while reducing the impact on AChE. This reagent is particularly relevant for research focused on neurodegenerative disorders. -
Cholinesterase (ChE) Inhibitor
Dihydro Donepezil is a potent cholinesterase (ChE) inhibitor, serving as a metabolite of Donepezil. It demonstrates significant biological activity, inhibiting acetylcholinesterase with IC50 values of 8.12 nM for bovine acetylcholinesterase (bAChE) and 11.6 nM for human acetylcholinesterase (hAChE). This compound is primarily utilized in research focused on neurodegenerative disorders and cognitive enhancement, contributing to studies on Alzheimer's disease and related pathways. -
AChE Inhibitor
AChE-IN-52 is an acetylcholinesterase (AChE) inhibitor that demonstrates notable antitumor activity, particularly against breast cancer MCF-7 cells. This compound significantly disrupts amino acid metabolism and inhibits the migration of MCF-7 cells. Furthermore, AChE-IN-52 exerts its anticancer effects through the regulation of Best1 and HIST1H2BJ, making it a valuable tool for research in cancer biology and therapeutic development. -
nAChR Modulator
JNJ-1930942 is a selective positive allosteric modulator of the α(7) nicotinic acetylcholine receptor (nAChR) that effectively crosses the blood-brain barrier. This compound facilitates heightened intracellular Ca2+ levels and promotes neurotransmission at synapses in the hippocampal dentate gyrus. Additionally, JNJ-1930942 has been shown to reverse sensory gating deficits in DBA/2 mouse models, making it a valuable tool for research in neuropsychiatric disorders and synaptic physiology. -
AchE Inhibitor
1,10-Bis(pyridinium)decane is a biscationic compound that acts as an acetylcholinesterase (AchE) inhibitor, demonstrating an IC50 of 25.8 nM. This reagent is valuable for research focused on neuropharmacology and the modulation of cholinergic signaling. Its specificity for AchE makes it suitable for studies investigating cognitive function and neurodegenerative diseases. -
AChE Inhibitor
Ganstigmine hydrochloride is an orally active inhibitor of acetylcholinesterase (AChE) that enhances the release of soluble amyloid precursor protein alpha (sAPPα) from neuroblastoma cells. This compound has been shown to increase acetylcholine levels in the prefrontal cortex of rats, making it a valuable tool in the study of cholinergic signaling. Ganstigmine hydrochloride is primarily utilized in research focused on neurological disorders, particularly Alzheimer's disease, to explore its implications in cognitive function and neuroprotection. -
BChE Inhibitor
BChE-IN-13 is a potent and selective inhibitor of Butyrylcholinesterase (BChE), targeting both equine and human forms with IC50 values of 0.22 μM and 0.016 μM, respectively. This orally active compound demonstrates significant potential for enhancing memory and cognitive functions, making it a valuable tool in Alzheimer's disease research. Its specificity for BChE positions it as a promising candidate for exploring therapeutic strategies in neurodegenerative disorders. -
AChE/BChE Inhibitor
AChE/BChE-IN-3 hydrochloride is a dual inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), exhibiting IC50 values of 6.08 μM against electric eel AChE and 0.383 μM against equine serum BChE. This compound is valuable for research focused on neurodegenerative diseases and cholinergic dysfunction, providing insights into the modulation of cholinergic signaling pathways. Its potent inhibitory effects make it a useful tool for studying enzyme kinetics and drug discovery related to cognitive decline. -
AchE Inhibitor
Icopezil is a selective inhibitor of acetylcholinesterase (AchE), a key enzyme involved in the hydrolysis of acetylcholine. Its ability to enhance cholinergic transmission makes it a valuable compound for research in Alzheimer's disease and other cognitive disorders. By increasing acetylcholine levels in the synaptic cleft, Icopezil offers potential insights into therapeutic strategies targeting cholinergic deficits in neurodegenerative conditions. -
Antispasmodic Agent
Pitofenone is a potent spasmolytic compound that primarily functions as an antispasmodic agent. It effectively inhibits acetylcholinesterase (AChE) activity in bovine erythrocytes and electric eel, exhibiting inhibition constants (Kis) of 36 μM and 45 μM, respectively. This compound is widely used in research applications focusing on muscle spasm relief and neuropharmacology. -
Cholinesterase (ChE) Inhibitor
(+)-Balanophonin is a phenolic compound that functions as an inhibitor of cholinesterase (ChE). It exhibits significant biological activities, including antioxidant, anti-inflammatory, anticancer, and antineurodegenerative effects. This compound is useful in research aimed at understanding neurodegenerative diseases and exploring potential therapeutic strategies for conditions associated with cholinergic system dysfunction. -
BChE Inhibitor
BChE-IN-10 is a potent mixed-type inhibitor of butyrylcholinesterase (BChE), exhibiting an IC50 value of 6.4 μM. Isolated from Bletilla striata, this compound effectively modulates cholinergic activity and holds potential in the investigation of Alzheimer’s disease (AD) pathology. Its application in neurodegenerative research makes it a valuable tool for studying BChE-related mechanisms and therapeutic strategies. -
Stable Isotope
Acephate-d3 is a deuterated analogue of Acephate, serving as a stable isotope. This compound primarily acts as an anticholinesterase insecticide, exhibiting cholinotoxic effects. While it demonstrates weak inhibition of rat acetylcholinesterase (AChE), it exhibits potent inhibition of AChE in cockroaches, making it valuable for research in insect physiology and pest management studies. -
AChE Inhibitor
Hydrangenol 8-O-glucoside is an acetylcholinesterase (AChE) inhibitor, demonstrating an IC50 value of 22.66 μM. Isolated from Hydrangea macrophyllus, this compound exhibits significant activity in inhibiting the PCA (passive cutaneous anaphylaxis) reaction. Its properties make it a useful tool for research on neurodegenerative diseases and allergic responses. -
BChE Inhibitor
S16–1029 is a selective and orally active butyrylcholinesterase (BChE) inhibitor, exhibiting IC50 values of 11.35 nM for equine BChE and 48.1 nM for human BChE. This compound is capable of crossing the blood-brain barrier (BBB), enabling it to effectively target the central nervous system (CNS). S16–1029 serves as a valuable tool for research in Alzheimer's disease (AD), contributing to the understanding of cholinergic dysfunction in neurodegenerative conditions. -
BChE Inhibitor
BChE-IN-14 is a selective butyrylcholinesterase (BChE) inhibitor, demonstrating IC50 values of 0.23 μM for equine BChE and 0.011 μM for human BChE. This compound exhibits favorable blood-brain barrier permeability and primary cell safety, making it suitable for in vivo studies. BChE-IN-14 has potential in restoring cognitive function, positioning it as a valuable tool for research into Alzheimer’s disease and related neurodegenerative conditions. -
AChE Reactivator
Pralidoxime methanesulfonate is a potent reactivator of acetylcholinesterase (AChE) that functions through direct nucleophilic attack by the oxime moiety on the phosphorus center of organophosphate-bound AChE. This reagent effectively restores AChE activity inhibited by nerve agents, making it critical in therapeutic interventions for organophosphate poisoning. Its primary applications include research into nerve agent effects and developing antidotes for chemical warfare agents. -
Cholinesterase (ChE) Inhibitor
Mimopezil is a cholinesterase (ChE) inhibitor that converts to the active metabolite Huperzine A in aqueous conditions. This compound demonstrates significant biological activity by enhancing acetylcholine levels, which is relevant in research focused on neurodegenerative diseases. Although Mimopezil exhibits low bioavailability in vivo, its effective metabolism to Huperzine A leads to increased concentrations in the bloodstream, making it a valuable tool for studying cognitive function and synaptic transmission. -
AChE Inhibitor
(3β,5α,6α,16β)-8,14-Didehydrocevane-3,6,16,20-tetrol is an acetylcholinesterase (AChE) inhibitor. At a concentration of 100 μg/mL, this compound demonstrates an in vitro inhibition rate of 12% against AChE, highlighting its potential utility in studies related to neurodegenerative diseases and cognitive disorders. Its application in biochemical research may provide insights into AChE-related pathways and therapeutic targets. -
AChE Inhibitor
Monardic acid A is a selective inhibitor of acetylcholinesterase (AChE), exhibiting an IC50 of 53.1 μM against AChE from electric eel. It displays weak inhibitory activity against human erythrocyte AChE (IC50 >100 μM) and negligible effects on butyrylcholinesterase (BChE). By inhibiting AChE activity, Monardic acid A effectively reduces acetylcholine breakdown, contributing to its anti-inflammatory properties and modulation of neurotransmitter release. This compound is sourced from lungwort (Pulmonaria officinalis) and thyme (Thymus gobicus), making it valuable for research in anti-inflammatory drug development and neurodegenerative disease therapeutics. -
Cholinesterase (ChE) Inhibitor
Isoprocarb-d3 is a deuterated form of Isoprocarb, a carbamate insecticide known for its efficacy in controlling pests such as rice paddy lice and leafhoppers. As an inhibitor of cholinesterase (ChE), Isoprocarb-d3 serves as a valuable tool in researching the mechanisms of action of carbamate insecticides and the effects of ChE inhibition. This compound can be utilized in studies related to pest management, neurobiology, and toxicology. -
Cholinesterase (ChE) Inhibitor
Drofenine is a potent competitive inhibitor of cholinesterase (ChE), with a Ki value of 3 μM. This compound effectively inhibits the breakdown of acetylcholine, leading to increased levels of this important neurotransmitter. Drofenine is utilized in research to study cholinergic signaling and its implications in neurodegenerative diseases, as well as to explore potential therapeutic avenues for conditions associated with impaired cholinergic transmission. -
Stable Isotope
Donepezil-d4 hydrochloride is a deuterium-labeled derivative of Donepezil hydrochloride, a reversible and selective inhibitor of acetylcholinesterase (AChE) with an IC50 of 6.7 nM. This compound demonstrates a strong selectivity for AChE over butyrylcholinesterase (BuChE) and exhibits neuroprotective effects against Aβ42-induced neurotoxicity. Donepezil-d4 is valuable for studying AChE interactions and pharmacokinetics in neurodegenerative disease research. -
BChE Inhibitor
BChE-IN-23 is a potent butyrylcholinesterase (BChE) inhibitor with an IC50 value of 21 nM. This compound is particularly valuable in Alzheimer's disease research, facilitating the study of cholinergic dysfunction associated with neurodegenerative conditions. Its selective inhibition of BChE may contribute to the development of therapeutic strategies for cognitive impairments in Alzheimer's disease. -
BuChE Inhibitor
BuChE-IN-4 is a selective butyrylcholinesterase (BuChE) inhibitor with an IC50 of 7.7 nM. It demonstrates mild antioxidant properties and neuroprotective effects while exhibiting a favorable lipophilicity and low toxicity profile. This compound is applicable in research focused on neurodegenerative diseases and exploring cholinergic signaling pathways. -
Acetylcholinesterase Inhibitor
Salithion is an acetylcholinesterase inhibitor that disrupts the hydrolysis of acetylcholine by binding to the enzyme's active site. This compound exhibits enantioselectivity, with distinct differences in the biological activity of its (R) and (S) enantiomers. Salithion serves as a valuable tool in neurotoxicology research and studies related to cholinergic signaling pathways. -
Cholinesterase (ChE) Inhibitor
AChE-IN-3 is a cholinesterase (ChE) inhibitor that demonstrates moderate inhibitory activity against acetylcholinesterase (AChE). Additionally, it exhibits strong nitric oxide (NO) inhibitory activity with an EC50 of 0.57 μM. This compound is suitable for research applications focused on neurodegenerative diseases and signaling pathways involving nitric oxide. -
Ach Inhibitor
AChE-IN-103 is a potent acetylcholinesterase (AChE) inhibitor that demonstrates log IC50 values of 1.477 and 2.2 in alignment models I and II, respectively. This compound plays a significant role in the research of Alzheimer’s disease, where it may help elucidate the mechanisms of cholinergic dysfunction. AChE-IN-103 is valuable for studies aimed at developing therapeutic strategies targeting cognitive decline associated with this neurodegenerative disorder. -
AChE Inhibitor
Pseudocoptisine acetate is a quaternary alkaloid derived from the benzylisoquinoline scaffold, isolated from Corydalis Tuber. It functions as an acetylcholinesterase (AChE) inhibitor, exhibiting an IC50 of 12.8 μM. This compound demonstrates significant anti-inflammatory and anti-amnestic properties, making it valuable for research in neurodegenerative diseases and cognitive impairment studies.
